Enter 2021.01.27 16:23 | Revision 2021.01.27 17:01
President Moon Jae-in said on the 27th, in relation to the corona pandemic (a global pandemic), “if the treatment that is being developed in Korea is successful, we will support it so that it can be supplied inclusively to the desired country.”
Among the’Korean-developed therapeutics’ mentioned by President Moon, the most promising candidate is Celltrion’s corona antibody treatment’Rekkironaju’. Celltrion has already completed production for 100,000 people so that Rekirona can supply it to medical sites as soon as it receives conditional approval from the Ministry of Food and Drug Safety. In addition, plans to produce treatments for up to 2 million people are in progress for global supply in accordance with the timing of approval in major overseas countries.
Rekironaju has completed phase 2 clinical trials. Celltrion will focus on the effect of reducing the incidence of critically ill patients, such as hospitalization and mortality, in phase 3 clinical trials according to the recommendation of the Ministry of Food and Drug Safety.